News
Gilead and MSD collab on Trodelvy/Keytruda breast cancer trial
Gilead Sciences and MSD – known as Merck in the US and Canada – have announced a clinical trial collaboration to test a combination of Gilead’s Trodelvy and MSD’s Keytruda for the first-line treatment of certain triple-negative breast cancer (TNBC) patients.